Zhi Tong Cai Jing·2025-09-20 06:23Core Viewpoint - The announcement of the completion of the ETHK building marks a significant strategic shift for the company towards becoming a leader in the Real World Assets (RWA) digitalization space, supported by a new brand identity that reflects its commitment to blockchain technology and compliance [2][4][10]. Group 1: Strategic Infrastructure - The ETHK building is the world's first core base focused on RWA digital technology research and ecosystem empowerment, located in Nanjing with a total area of approximately 70,000 square meters [3][4]. - The building serves a dual purpose: as a physical base for research and collaborative innovation, and as a trusted technology development and output hub, expected to gather over 5,000 technical experts and R&D engineers [4][5]. Group 2: RWA Ecosystem Layout - The recent logo update and building completion represent the company's "second entrepreneurship," fully transitioning towards the RWA sector, which involves the tokenization of real-world assets [5][6]. - The RWA market is projected to reach a total locked value (TVL) of $12.5 billion by June 2025, reflecting a 124% increase from 2024, with a global market size expected to hit $16.1 trillion by 2030 [5][6]. Group 3: Innovative Business Model - The company has established a strategic partnership with Renhe Pharmaceutical to create the world's first OTC vertical RWA exchange, showcasing its innovative "exchange within an exchange" model [6][7]. - This model aims to provide on-chain financial infrastructure for leading enterprises across various industries, facilitating the tokenization of intangible assets and enhancing global asset flow [7][8]. Group 4: Value Creation and Market Impact - The company's RWA strategy aims to create multidimensional value, contributing to national strategies and public welfare, while enhancing the global OTC industry's digital transformation [8][9]. - The strategic collaboration with Renhe Pharmaceutical is expected to optimize asset structures and enable the introduction of innovative OTC products from global markets into China, benefiting both companies and consumers [8][9].